NDAINTRAVESICALSOLUTION
Approved
Apr 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CYSTO-CONRAY II (iothalamate meglumine) by Guerbet is clinical pharmacology the most important characteristic of contrast media is the iodine content. First approved in 1972.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY The most important characteristic of contrast media is the iodine content. The relatively high atomic weight of iodine contributes sufficient radiodensity for radiographic contrast. Following instillation by sterile catheter, Cysto-Conray II provides for visualization of the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Worked on CYSTO-CONRAY II at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.